Syndax Shares Face Market Pressure Despite Regulatory Win

Quarterly Report Looms as Critical Test

Syndax Pharmaceuticals finds itself navigating turbulent market conditions following a significant regulatory achievement. The biotech firm’s stock has experienced substantial selling pressure, creating an apparent contradiction where corporate progress clashes with investor skepticism. This downturn stems from a combination of safety concerns surrounding its flagship drug and notable insider selling activity.

All eyes are on Syndax’s upcoming financial disclosure scheduled for Tuesday, November 4. The company will release its third-quarter 2025 results, with market experts anticipating specific performance metrics:

• Earnings per share: Projected loss of ($0.73)
• Revenue forecast: $49.08 million